ストックスクリーナーアプリを入手
4.91
1.60%
-0.08
アフターアワーズ：
4.92
0.010
+0.20%
Compass Therapeutics Inc (CMPX) 最新ニュース
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com UK
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com UK
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics details cash runway and pipeline progress - TipRanks
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com India
Compass Therapeutics Provides Corporate Update - Yahoo Finance
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026 - marketscreener.com
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care - One News Page
Compass Therapeutics announces key leadership appointments - marketscreener.com
Compass Therapeutics appoints new chief commercial and medical officers - Investing.com
Compass Therapeutics Announces Key Leadership Appointments - The Manila Times
New leaders join Compass Therapeutics as it advances cancer drugs - Stock Titan
William Blair Initiates Compass Therapeutics at Outperform - marketscreener.com
William Blair initiates coverage on Compass Therapeutics stock with Outperform rating - Investing.com Canada
Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study? - RTTNews
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next? - Defense World
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5%What's Next? - MarketBeat
Compass Therapeutics files for up to $400 million mixed shelf offeringSEC filing - marketscreener.com
Compass Therapeutics Files $400 Million Mixed Shelf - marketscreener.com
Wedbush Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment - Insider Monkey
Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment - Finviz
Published on: 2025-12-21 11:19:43 - moha.gov.vn
Compass Therapeutics Earnings Notes - Trefis
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance
Is Compass Therapeutics Inc. stock a defensive play in 2025Weekly Loss Report & Technical Confirmation Alerts - DonanımHaber
How Compass Therapeutics Inc. stock reacts to global recession fearsQuarterly Earnings Summary & Community Verified Swing Trade Signals - DonanımHaber
Why Compass Therapeutics Inc. stock could outperform in 2025July 2025 Technicals & Fast Gain Swing Alerts - DonanımHaber
12 Best Multibagger Stocks to Buy Heading into 2026 - Insider Monkey
Patterns Watch: How Compass Therapeutics Inc. stock reacts to global recession fearsPrice Action & Low Risk Profit Maximizing Plans - DonanımHaber
Why analysts remain bullish on Compass Therapeutics Inc. stockJuly 2025 Reactions & Precise Buy Zone Tips - Улправда
How Compass Therapeutics Inc. stock trades during market volatilityWeekly Stock Recap & Comprehensive Market Scan Reports - Улправда
Signal Recap: Is Compass Therapeutics Inc. stock in correction or buying zone2025 Earnings Impact & Low Drawdown Investment Ideas - ulpravda.ru
Published on: 2025-12-19 03:17:09 - Улправда
Published on: 2025-12-19 02:57:37 - Улправда
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference - Yahoo Finance
Wall Street analysts think Compass Therapeutics, Inc. (CMPX) could surge 134.14%: Read this before placing a bet - MSN
Here's why Compass Therapeutics, Inc. (CMPX) is a great momentum stock to buy - MSN
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet - Zacks Investment Research
An analyst sees good growth prospects for Compass Therapeutics Inc (CMPX) - Setenews
Vivo Capital LLC Purchases 2,487,443 Shares of Compass Therapeutics, Inc. $CMPX - MarketBeat
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy - sharewise.com
Compass Therapeutics announces public offering of common stock By Investing.com - Investing.com Nigeria
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Citizens Jmp - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Citizens Jmp - Defense World
Analysts Are Bullish on These Healthcare Stocks: Schrodinger (SDGR), Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Citizens Initiates Coverage of Compass Therapeutics (CMPX) with Market Outperform Recommendation - Nasdaq
Compass Therapeutics (NASDAQ:CMPX) Trading Down 6%Time to Sell? - MarketBeat
CMPX Analyst Rating Update: Citizens Initiates Coverage with Mar - GuruFocus
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Cantor Fitzgerald Initiates Compass Therapeutics at Overweight - marketscreener.com
Cantor Fitzgerald initiates Compass Therapeutics stock with Overweight rating By Investing.com - Investing.com UK
Compass Therapeutics stock initiated at Market Outperform by Citizens - Investing.com Canada
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):